Home Companies Catalysts Deep Dives
Neupro rotigotine APPROVED
Drug Profile
ModalitySmall molecule
RouteTransdermal
Therapy AreaNeurology
Launch2007-05-09
US LOE2020-01-01
Peak Sales Est$400M
Formulations[{"id":"neupro-patch","doses":"1mg, 2mg, 3mg, 4mg, 6mg, 8mg patch","route":"Transdermal","setting":"
Companies
UCB (ORIGINATOR)100%
Mechanism: Dopamine agonist
Expert: Stimulates dopamine receptors to improve motor function
Everyday: Stimulates dopamine receptors to improve motor function
Targets: ["DOPAMINE"]
Revenue History
PeriodRevenue ($M)
2023$295M
2024$268M
Programs (2)
IndicationStageKey StudyRegional Status
Restless legs syndromeAPPROVEDSP790/792[{"stage":"APPROVED","region":"US","approval_date":"2012-04"},{"stage":"APPROVED
Parkinson's diseaseAPPROVEDSP512/650[{"stage":"APPROVED","region":"US","approval_date":"2007-05"},{"stage":"APPROVED
Notes
Rotigotine transdermal patch, a non-ergot dopamine agonist for Parkinson's disease and restless legs syndrome. First dopamine agonist available as a once-daily patch, providing continuous drug delivery and improved compliance.
Data from Supabase · Updated 2026-03-24